{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-101492","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2026-09-18T21:11:43+00:00","discovered_at":"2026-09-18T21:14:00.783741+00:00","generated_at":"2026-09-18T21:14:06.232562+00:00","sec_items":["3.01","8.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"InMed receives Nasdaq delisting notice for equity shortfall; merger to cure","bullets":["Nasdaq notice on 9/16/2026: shareholders' equity $1,075,007 vs $2.5M required under Rule 5550(b)(1).","45 days to submit compliance plan (by Nov 2, 2026); up to 180-day extension possible until Mar 15, 2027.","Deficiency driven by Merger expenses with Mentari; combined company expects ~$490M gross proceeds, closing Q4 2026.","Stock up ~99.8% since Merger announcement; shares continue trading on Nasdaq under INM."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-101492","json":"https://secwatch.observer/filing/0001213900-26-101492.json","markdown":"https://secwatch.observer/filing/0001213900-26-101492.md","text":"https://secwatch.observer/filing/0001213900-26-101492.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000121390026101492/0001213900-26-101492-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000121390026101492/ea0305769-8k_inmed.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-18T21:14:06.232562+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}